[go: up one dir, main page]

WO2025188180A8 - Agents de ciblage d'erbb-2 et d'erbb3 destinés à être utilisés dans le traitement de cellules malignes ou de cancers qui ont une expression de nrg1 élevée - Google Patents

Agents de ciblage d'erbb-2 et d'erbb3 destinés à être utilisés dans le traitement de cellules malignes ou de cancers qui ont une expression de nrg1 élevée

Info

Publication number
WO2025188180A8
WO2025188180A8 PCT/NL2025/050102 NL2025050102W WO2025188180A8 WO 2025188180 A8 WO2025188180 A8 WO 2025188180A8 NL 2025050102 W NL2025050102 W NL 2025050102W WO 2025188180 A8 WO2025188180 A8 WO 2025188180A8
Authority
WO
WIPO (PCT)
Prior art keywords
erbb
cancers
treatment
malignant cells
targeting agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/NL2025/050102
Other languages
English (en)
Other versions
WO2025188180A1 (fr
Inventor
Arie Berdinus BRINKMAN
Jeroen Jilles LAMMERTS VAN BUEREN
Sidney Peter WALKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merus BV
Original Assignee
Merus BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus BV filed Critical Merus BV
Publication of WO2025188180A1 publication Critical patent/WO2025188180A1/fr
Publication of WO2025188180A8 publication Critical patent/WO2025188180A8/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne le domaine des agents de ciblage de d'ErbB-2 et/ou d'ErbB3, tels que des anticorps se liant à ErbB-2 et/ou ErbB3. En particulier, l'invention concerne le domaine des anticorps thérapeutiques (humains) pour le traitement d'une cellule, d'une tumeur ou d'un cancer ErbB-2/ErbB -3-positifs. Plus particulièrement, l'invention concerne le traitement de cellules malignes, de tumeurs ou de cancers comprenant des niveaux d'expression de NRG1 élevés.
PCT/NL2025/050102 2024-03-04 2025-03-03 Agents de ciblage d'erbb-2 et d'erbb3 destinés à être utilisés dans le traitement de cellules malignes ou de cancers qui ont une expression de nrg1 élevée Pending WO2025188180A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2037175 2024-03-04
NL2037175 2024-03-04

Publications (2)

Publication Number Publication Date
WO2025188180A1 WO2025188180A1 (fr) 2025-09-12
WO2025188180A8 true WO2025188180A8 (fr) 2025-10-02

Family

ID=90717914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2025/050102 Pending WO2025188180A1 (fr) 2024-03-04 2025-03-03 Agents de ciblage d'erbb-2 et d'erbb3 destinés à être utilisés dans le traitement de cellules malignes ou de cancers qui ont une expression de nrg1 élevée

Country Status (2)

Country Link
TW (1) TW202536421A (fr)
WO (1) WO2025188180A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2631727T3 (es) * 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Anticuerpos contra el ErbB3 y usos de los mismos
WO2013157953A1 (fr) 2012-04-20 2013-10-24 Merus B.V. Procédés et moyens de production de molécules de type ig
WO2015025866A1 (fr) * 2013-08-20 2015-02-26 独立行政法人国立がん研究センター Nouveau gène de fusion détecté dans un cancer du poumon
ES3006007T3 (en) 2014-02-28 2025-03-17 Merus Nv Antibody that binds erbb-2 and erbb-3
SG11201908833TA (en) * 2017-03-31 2019-10-30 Merus Nv Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
TW202313987A (zh) * 2021-06-03 2023-04-01 荷蘭商美勒斯公司 用於測定nrg1融合多核苷酸的液態檢體測定法

Also Published As

Publication number Publication date
TW202536421A (zh) 2025-09-16
WO2025188180A1 (fr) 2025-09-12

Similar Documents

Publication Publication Date Title
Ortholan et al. Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
WO2004113571A3 (fr) Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate
MX2024008496A (es) Uso de un antisentido para la preparacion de un medicamento para tratar canceres.
ZA201907225B (en) Treatment of her2 positive cancers
ZA202304965B (en) Combination therapy for treating cancer
MX2023007436A (es) Arn terapeutico para tratar cancer.
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2
WO2025188180A8 (fr) Agents de ciblage d'erbb-2 et d'erbb3 destinés à être utilisés dans le traitement de cellules malignes ou de cancers qui ont une expression de nrg1 élevée
WO2003013431A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du sein
WO2023174925A8 (fr) Anticorps anti-gpc3xcd28 et anti-gpc3xcd3 bispécifiques et leur combinaison pour la destruction ciblée de cellules malignes positives à gpc3
WO2005051990A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du sein
MX2025005779A (es) Conjugado de anticuerpo-farmaco, metodo de preparacion y uso del mismo
MX2025006808A (es) Productos terapeuticos dirigidos al receptor de somatostatina subtipo 2 (sst2r) y usos de la misma
MX2020013883A (es) Tratamientos oncológicos con agentes de zinc.
WO2021127556A8 (fr) Procédés de traitement du cancer comprenant un rayonnement à faible dose
MX2021005169A (es) Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido.
SG148035A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
Perera et al. The role of radiotherapy in metastatic bladder cancer
WO2022122765A3 (fr) Polythérapie à base d'anticorps et de taxane
Mukaida et al. Clinical evaluation of adjuvant chemoradiotherapy with CDDP, 5-FU, and VP-16 for advanced esophageal cancer
Ravery Brachytherapy versus radical prostatectomy.
TW202604543A (zh) 於實體腫瘤的ｐ２１工程化單核球及放射療法
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
Santiago et al. Outcomes of combination therapy for stage IIA–IIIB cervical cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25710572

Country of ref document: EP

Kind code of ref document: A1